The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model

Journal of Bone and Mineral Research

Volumn 26, Issue 6, 2011, Pages 1283-1294

  Sampson, Erik R ^a   Martin, Brad A ^a   Morris, Aimee E ^a   Xie, Chao ^a   Schwarz, Edward M ^a   O'Keefe, Regis J ^a   Rosier, Randy N ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

MATRIX PRODUCTION; MET; OSTEOLYSIS; OSTEOSARCOMA; PF 2341066; XENOGRAFT

Indexed keywords

CRIZOTINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MATRIX; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOSARCOMA CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BIOLOGICAL AVAILABILITY; BONE MATRIX; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOGENESIS; OSTEOLYSIS; OSTEOSARCOMA; PHOSPHORYLATION; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958803354     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.336     Document Type: Article

References (39)

1. Gorlick R, Khanna C,. Osteosarcoma. J Bone Miner Res. 2009; 25: 683-691.
2. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ,. Osteosarcoma. J Am Acad Orthop Surg. 2009; 17: 515-527.
3. De Maria R, Miretti S, Iussich S, et al. Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J Pathol. 2009; 218: 399-408.
4. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF,. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915-925. (Pubitemid 37493640)
5. Christensen JG, Burrows J, Salgia R,. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005; 225: 1-26. (Pubitemid 40732764)
6. Sonnenberg E, Weidner KM, Birchmeier C,. Expression of the met-receptor and its ligand, HGF-SF during mouse embryogenesis. Exs. 1993; 65: 381-394.
7. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 1997; 94: 11445-11450. (Pubitemid 27451018)
8. Furge KA, Kiewlich D, Le P, et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A. 2001; 98: 10722-10727. (Pubitemid 32878688)
9. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 1997; 94: 701-706.
10. Liang TJ, Reid AE, Xavier R, Cardiff RD, Wang TC,. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest. 1996; 97: 2872-2877. (Pubitemid 26197101)
11. Jeffers M, Rong S, Woude GF,. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med. 1996; 74: 505-513. (Pubitemid 26306792)
12. Tseng JR, Kang KW, Dandekar M, et al. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 2008; 49: 129-134.
13. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 2004; 6: 61-73. (Pubitemid 38903162)
14. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003; 63: 7345-7355. (Pubitemid 37413476)
15. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007; 67: 4408-4417. (Pubitemid 46815090)
16. Timofeevski SL, McTigue MA, Ryan K, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry. 2009; 48: 5339-5349.
17. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994; 77: 261-271. (Pubitemid 24138623)
18. Ferracini R, Di Renzo MF, Scotlandi K, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene. 1995; 10: 739-749.
19. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF,. Met expression and sarcoma tumorigenicity. Cancer Res. 1993; 53: 5355-5360. (Pubitemid 23342148)
20. Patane S, Avnet S, Coltella N, et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 2006; 66: 4750-4757.
21. Coltella N, Manara MC, Cerisano V, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. Faseb J. 2003; 17: 1162-1164.
22. Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM,. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res. 2008; 466: 2168-2175.
23. Zillhardt M, Christensen JG, Lengyel E,. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010; 12: 1-10.
24. Comoglio PM, Giordano S, Trusolino L,. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008; 7: 504-516. (Pubitemid 351767118)
25. Kwak EL, Amidge DR, Clark J, et al. 2009; Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 Joint ECCO 15-34TH ESMO Multidisciplinary Congress, vol. 7 European Journal of Cancer Supplements, Berlin, pp 8.
26. Gonzatti-Haces M, Seth A, Park M, Copeland T, Oroszlan S, Vande Woude GF,. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A. 1988; 85: 21-25.
27. Dean M, Park M, Le Beau MM, et al. The human met oncogene is related to the tyrosine kinase oncogenes. Nature. 1985; 318: 385-388. (Pubitemid 16198499)
28. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008; 68: 3389-3395.
29. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-1037. (Pubitemid 32267972)
30. McNeil C,. Herceptin raises its sights beyond advanced breast cancer. J Natl Cancer Inst. 1998; 90: 882-883. (Pubitemid 28304154)
31. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA,. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 2007; 8: 513-524. (Pubitemid 46823060)
32. Walkley CR, Qudsi R, Sankaran VG, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008; 22: 1662-1676. (Pubitemid 351846845)
33. Berman SD, Calo E, Landman AS, et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A. 2008; 105: 11851-11856.
34. Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int. 1998; 48: 757-762. (Pubitemid 28455692)
35. Rong S, Bodescot M, Blair D, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol. 1992; 12: 5152-5158.
36. Guo Y, Xie J, Rubin E, et al. Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. Cancer Res. 2008; 68: 3350-3360.
37. Rees H, Williamson D, Papanastasiou A, et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors. 2006; 24: 197-208. (Pubitemid 44669350)
38. Luu HH, Kang Q, Park JK, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 2005; 22: 319-329. (Pubitemid 41374288)
39. Niswander LM, Guenther LM, Mendoza A, et al. 2010; Effect of modulation of MET with the small molecule inhibitor PF-04217903 on osteosarcoma metastasis in vivo 2010 American Society of Clinical Oncology, vol. 28 Journal of Clinical Oncology, Chicago, pp abstr 9567.